Key Points
- CAO Amir Cohen sold 40,575 shares of Strata Critical Medical on May 22 at an average price of $5.91, totaling about $239,798. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and his direct holdings fell by 21.15%.
- The company recently beat earnings expectations, reporting $0.03 EPS versus the consensus estimate of -$0.04, on revenue of $67.38 million. Despite the beat, analysts still expect a loss of $0.14 EPS for the current fiscal year.
- Wall Street’s view is mixed but constructive, with a consensus rating of “Moderate Buy” and a target price of $8.00. The stock was trading near $6.14, close to its 52-week high of $6.27.
Strata Critical Medical (NASDAQ:SRTA - Get Free Report) CAO Amir Cohen sold 10,300 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $5.79, for a total transaction of $59,637.00. Following the sale, the chief accounting officer directly owned 191,838 shares of the company's stock, valued at $1,110,742.02. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Amir Cohen also recently made the following trade(s):
- On Friday, May 22nd, Amir Cohen sold 40,575 shares of Strata Critical Medical stock. The shares were sold at an average price of $5.91, for a total transaction of $239,798.25.
Strata Critical Medical Price Performance
Shares of NASDAQ SRTA opened at $6.14 on Wednesday. Strata Critical Medical has a 52-week low of $3.40 and a 52-week high of $6.27. The company's fifty day moving average is $4.85. The stock has a market cap of $531.29 million, a PE ratio of -76.75 and a beta of 2.15.
Strata Critical Medical (NASDAQ:SRTA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.07. Strata Critical Medical had a net margin of 20.56% and a negative return on equity of 4.06%. The company had revenue of $67.38 million during the quarter. On average, sell-side analysts forecast that Strata Critical Medical will post -0.14 earnings per share for the current fiscal year.
Institutional Trading of Strata Critical Medical
A number of institutional investors have recently added to or reduced their stakes in the business. Seelaus Asset Management LLC boosted its position in Strata Critical Medical by 32.7% during the 1st quarter. Seelaus Asset Management LLC now owns 24,350 shares of the company's stock worth $102,000 after purchasing an additional 6,000 shares during the period. Granite Investment Partners LLC boosted its position in Strata Critical Medical by 77.0% during the 1st quarter. Granite Investment Partners LLC now owns 18,181 shares of the company's stock worth $76,000 after purchasing an additional 7,911 shares during the period. Bank of America Corp DE boosted its position in Strata Critical Medical by 16.2% during the 1st quarter. Bank of America Corp DE now owns 181,574 shares of the company's stock worth $759,000 after purchasing an additional 25,379 shares during the period. Quantinno Capital Management LP boosted its position in Strata Critical Medical by 98.7% during the 1st quarter. Quantinno Capital Management LP now owns 143,239 shares of the company's stock worth $599,000 after purchasing an additional 71,155 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in Strata Critical Medical during the 1st quarter worth $537,000. 47.36% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
SRTA has been the subject of several research reports. Craig Hallum initiated coverage on shares of Strata Critical Medical in a research note on Wednesday, March 25th. They set a "buy" rating and a $8.00 price objective for the company. Zacks Research raised shares of Strata Critical Medical to a "hold" rating in a research report on Thursday, March 26th. B. Riley Financial assumed coverage on shares of Strata Critical Medical in a research report on Wednesday, March 25th. They set a "buy" rating and a $8.00 price target for the company. Finally, Weiss Ratings raised shares of Strata Critical Medical from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Strata Critical Medical has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.
Read Our Latest Stock Report on Strata Critical Medical
Strata Critical Medical Company Profile
(
Get Free Report)
Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
